No Data
On May 2, He Yu-B (02256.HK) spent 2.38 million HKD to repurchase 0.3 million shares.
Gelonghui, on May 2, announced that He Yu-B (02256.HK) spent 2.38 million Hong Kong dollars to repurchase 0.3 million shares on May 2.
He Yu-B (02256.HK) spent 0.77 million HKD to repurchase 0.1 million shares on April 30.
On April 29, Gelonghui announced that He Yu-B (02256.HK) will spend HKD 0.77 million to repurchase 0.1 million shares on April 30.
On April 29, Hanyu-B (02256) spent 0.7605 million Hong Kong dollars to buy back 0.1 million shares.
Hanyu-B (02256) announced that on April 29, 2025, the company invested 0.7605 million Hong Kong dollars...
Abbisko Cayman Limited's (HKG:2256) 9.4% Gain Last Week Benefited Both Individual Investors Who Own 52% as Well as Insiders
On April 28, He Yu-B (02256.HK) spent 2.2351 million Hong Kong dollars to repurchase 0.3 million shares.
Gelonghui April 28丨 Heyu-B (02256.HK) announced that on April 28, 2025, it repurchased 0.3 million shares at a cost of 2.2351 million Hong Kong dollars, with a repurchase price of 7.33-7.52 Hong Kong dollars per share.
He Yü-B (02256.HK): Will present the latest breakthrough preclinical research results of ABSK112 (EGFR exon 20 insertion) and three other studies at the 2025 AACR Annual Meeting.
Gelonghui April 28th丨He Yu-B (02256.HK) announced that it presented four groundbreaking preclinical research results in poster format at the 2025 American Association for Cancer Research Annual Meeting held in Chicago, Illinois, USA, from April 25 to April 30, 2025. These research results include EGFR exon 20 insertion inhibitor ABSK112, PRMT5*MTA inhibitor ABSK131, pan-KRAS inhibitor ABK-KRAS-1, and a study on potential resistance to KRAS G12C inhibitors.
